600 cancer patients to help unlock secrets of immunotherapy success
NCT ID NCT07427186
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy before surgery. Researchers will collect blood and tumor samples at several time points to see how the immune system responds. The goal is to find biological markers that show whether the treatment is working. Participants will be monitored for up to 5 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict which early-stage cancer patients will benefit most from immunotherapy before surgery.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results might not apply to all cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chu Rangueil
Toulouse, 31400, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hopital Larrey
Toulouse, 31400, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Universitaire Du Cancer de Toulouse - Oncopole
Toulouse, 31059, France
Contact Phone: •••-•••-•••• Email: •••••@•••••